November 1985

Imipenem/Cilastatin for the Treatment of Infections in Hospitalized Children

Author Affiliations

From the Division of Infectious Diseases, The Children's Hospital of Philadelphia (Drs Alpert, Campos, and Plotkin and Mr Bloh), and the Department of Pediatrics, University of Rochester (NY) Medical Center (Drs Dagan, Connor, and Powell). Dr Campos is now with The Children's Hospital National Medical Center, Washington, DC.

Am J Dis Child. 1985;139(11):1153-1156. doi:10.1001/archpedi.1985.02140130091038

• Imipenem is the first of a new class of βlactam antimicrobial agents with potent in vitro activity against most bacterial pathogens that cause infections in children. We studied, prospectively, the clinical efficacy and toxicity of imipenem/cilastatin in 40 children with proved or suspected bacterial infection. A dose of 100 mg/kg/day of imipenem was given to children younger than 3 years of age, while children older than 3 years of age received 60 mg/kg/day. Twenty-nine organisms were isolated from 26 patients. Infections treated included cellulitis, osteomyelitis, septic arthritis, lymphadenitis, renal infections, wound infections, and pneumonia. Bacteria isolated included Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae, and Pseudomonas aeruginosa. All patients responded favorably to treatment, with defervescence and improvement of symptoms. All of the infecting bacteria were susceptible to imipenem. Imipenem/cilastatin was well tolerated, with no serious side effects, and appeared to be an effective and safe antimicrobial agent in the treatment of the population studied.

(AJDC 1985;139:1153-1156)